Jiexin Deng

ORCID: 0009-0004-0995-0659
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pharmacogenetics and Drug Metabolism
  • Statistical Methods in Clinical Trials
  • Nanoparticle-Based Drug Delivery
  • Drug Solubulity and Delivery Systems
  • Cardiomyopathy and Myosin Studies
  • Advanced Drug Delivery Systems
  • Muscle Physiology and Disorders
  • Cancer Treatment and Pharmacology
  • Sphingolipid Metabolism and Signaling
  • Receptor Mechanisms and Signaling
  • Biosimilars and Bioanalytical Methods
  • Circadian rhythm and melatonin
  • Hormonal Regulation and Hypertension
  • Cancer therapeutics and mechanisms
  • Chronic Myeloid Leukemia Treatments
  • Neurogenetic and Muscular Disorders Research
  • Epigenetics and DNA Methylation
  • HER2/EGFR in Cancer Research
  • Health Systems, Economic Evaluations, Quality of Life
  • Lung Cancer Treatments and Mutations
  • Drug Transport and Resistance Mechanisms
  • Ion Transport and Channel Regulation
  • Metal complexes synthesis and properties
  • Mesoporous Materials and Catalysis
  • Pancreatic function and diabetes

Henan University
2013-2024

University of Florida
2014-2017

Columbus Oncology and Hematology Associates
2016

Reckitt Benckiser (United States)
2016

University of North Carolina at Chapel Hill
2010

10.1016/j.ijpharm.2010.02.013 article EN International Journal of Pharmaceutics 2010-02-22

Abstract There has been controversy regarding whether bioavailability of certain oral oncology drugs should be maximized by taking these medications with food, irrespective label instructions in the dosing and administration section. To provide insight into this controversy, we conducted an in‐depth analysis for antineoplastic approved Food Drug Administration 2000‐2016 identified important issues influencing food labeling decisions. Furthermore, a case study involving sonidegib, drug...

10.1002/cpdd.416 article EN Clinical Pharmacology in Drug Development 2017-12-02

FDA recommendations to manage polymorphic CYP-mediated drug-drug interactions (DDIs) and gene-drug (GDIs) are typically similar. However, DDIs may not always reliably predict GDIs because the victim drug have multiple metabolic pathways perpetrator affect enzymes or transporters. Consequently, it is of great interest both pharmaceutical industry regulatory agencies determine if DDI studies can be leveraged inform vice versa for dose adjustment labeling. The objective this study was...

10.1002/jcph.743 article EN The Journal of Clinical Pharmacology 2016-04-04

Abstract Duchenne muscular dystrophy (DMD) is a rare X‐linked recessive disorder characterized by loss‐of‐function mutations in the gene encoding dystrophin. These lead to progressive functional deterioration including muscle weakness, respiratory insufficiency, and musculoskeletal deformities. Three‐dimensional gait analysis (3DGA) has been used as tool analyze pathology through quantification of altered joint kinematics, kinetics, activity patterns. Among 3DGA indices, Gait Profile Score...

10.1002/psp4.13126 article EN cc-by-nc-nd CPT Pharmacometrics & Systems Pharmacology 2024-03-27

10.17615/by6w-g860 article EN Carolina Digital Repository (University of North Carolina at Chapel Hill) 2010-01-01

Nano-carrier systems have become an attractive alternative in the formulation of hydrophobic drugs, and number scientific patent publications per year on nanoparticles has experienced exponential growth since 2000. As these drugs are carried by different nano-carriers, their pharmacokinetics (PK) biodistribution will be greatly affected. Therefore, PK important parameters to evaluate nano-systems, which commonly performed HPLC. This study looks at certain issues extraction HPLC analysis...

10.1166/jbn.2010.1104 article EN Journal of Biomedical Nanotechnology 2010-04-01

Abstract Warfarin has a long record of safe and effective clinical use, it remains one the most commonly prescribed drugs for prevention treatment thromboembolic conditions even in era direct oral anticoagulants. To address its large interindividual variability narrow therapeutic window, Clinical Pharmacogenetics Implementation Consortium recommended using pharmacogenetic dosing algorithms, such as ones developed by International (IWPC) Gage et al, to dose warfarin when genotype information...

10.1002/jcph.2197 article EN The Journal of Clinical Pharmacology 2022-12-22

Objective Warfarin has a narrow therapeutic window and large variability in dosing that are affected by clinical genetic factors. To help guide the of warfarin, Clinical Pharmacogenetics Implementation Consortium recommended use pharmacogenetic algorithms, such as ones developed International (IWPC) Gage et al. when genotype information is available. Methods In this study, simulations were performed Chinese cohorts to explore how differences between Western (by IWPC al.) algorithms Miao...

10.1097/fpc.0000000000000545 article EN Pharmacogenetics and Genomics 2024-09-11

Prenatal alcohol exposure, especially during early pregnancy, can lead to fetal syndrome. The pharmacological and toxicological mechanisms of ethanol are related the effects ceramide. In this study, we established an exposure model in wild-type mice knockout for key enzyme involved ceramide metabolism, sphingomyelin synthase 2. This received daily intragastric administration 25% ethanol, pups were used at postnatal days 0, 7, 14, 30 experiments. Serology immunofluorescence staining found...

10.3969/j.issn.1673-5374.2013.23.008 article EN PubMed 2013-08-15
Coming Soon ...